Advancing Inclusive Clinical Research for Rare Diseases at BioMarin
"Because of the advances in technology platforms, H1 being one of them, we are able to decrease the time it takes for the initial vetting of our sites, and this has proven to be an efficiency gain for us in the clinical operations world."
See how BioMarin advances inclusive research for rare disease trials through technology for better site selection. Through H1, they are able to rapidly identify viable study sites that provide access to diverse patient populations across specific demographics and locations. By inputting key criteria like indication, ICD codes, and geographic regions, H1’s AI-powered insights allow BioMarin to efficiently identify the right sites for patient enrollment in rare disease trials.
Discover how BioMarin partners with H1 to transform inclusive access to rare disease trials.
Click below to listen to the full interview: